Keyphrases
AIDS/HIV
59%
Antiretroviral Therapy
45%
People Living with HIV (PLHIV)
39%
HIV Patients
30%
COVID-19
22%
REPRIEVE
20%
HIV Infection
19%
AIDS Clinical Trials
18%
CD4 Count
18%
Human Immunodeficiency Virus Type 1 (HIV-1)
17%
Dyslipidemia
15%
New York City
14%
Cardiovascular Risk
13%
Atorvastatin
11%
Randomized Trial
10%
Highly Active Antiretroviral Therapy (HAART)
9%
Pitavastatin
9%
Human Immunodeficiency Virus Infection
9%
Immune Activation
9%
Coronary Artery Disease
8%
Ritonavir
8%
Placebo
8%
Cardiovascular Disease
7%
Efavirenz
7%
Infectious Diseases Society of America
7%
Inflammation
7%
Hospitalized Patients
7%
Pharmacokinetics
6%
Cell Count
6%
Confidence Interval
6%
Statins
6%
Protease Inhibitors
6%
Opportunistic Infections
6%
Vascular Events
6%
Primary Care
5%
Pharmacokinetic Interaction
5%
Titer
5%
Fostemsavir
5%
Heavily Treatment Experienced
5%
HIV Care
5%
Mycobacterium Avium Complex
5%
Randomized Placebo-controlled Trial
5%
Antiretroviral
5%
Cytomegalovirus
5%
Cardiovascular Prevention
5%
Low-density Lipoprotein Cholesterol (LDL-C)
5%
Pharmacology, Toxicology and Pharmaceutical Science
HIV
100%
Human Immunodeficiency Virus Infection
20%
Clinical Trial
18%
Disease
17%
Cardiovascular Disease
15%
Infection
15%
Pharmacokinetics
14%
Dyslipidemia
12%
Placebo
11%
Inflammation
9%
Pitavastatin
9%
Pravastatin
8%
Coronavirinae
8%
Efavirenz
8%
Proteinase Inhibitor
7%
Cardiovascular Risk
6%
SARS Coronavirus
6%
Adverse Event
5%
Biological Marker
5%
Low Density Lipoprotein Cholesterol
5%
Medicine and Dentistry
Human Immunodeficiency Virus
94%
Antiretroviral Therapy
23%
COVID-19
21%
Infection
20%
Human Immunodeficiency Virus Infection
14%
Disease
13%
Cardiovascular Disease
11%
Cell Count
10%
Severe Acute Respiratory Syndrome Coronavirus 2
9%
Immunity
9%
Coronary Artery Disease
8%
Clinical Trial
8%
Placebo
8%
Primary Health Care
7%
Cardiovascular System
6%
Medicine
6%
Biological Marker
6%
Highly Active Antiretroviral Therapy
5%
Fostemsavir
5%
Cardiovascular Risk
5%